"Zidovudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
| Descriptor ID |
D015215
|
| MeSH Number(s) |
D03.383.742.680.705.950 D13.570.230.500.950 D13.570.230.855.950 D13.570.685.705.950
|
| Concept/Terms |
Zidovudine- Zidovudine
- Azidothymidine
- AZT Antiviral
- 3'-Azido-3'-deoxythymidine
- 3' Azido 3' deoxythymidine
- AZT (Antiviral)
- 3'-Azido-2',3'-Dideoxythymidine
- 3' Azido 2',3' Dideoxythymidine
- AZT, Antiviral
- Antiviral AZT
|
Below are MeSH descriptors whose meaning is more general than "Zidovudine".
Below are MeSH descriptors whose meaning is more specific than "Zidovudine".
This graph shows the total number of publications written about "Zidovudine" by people in this website by year, and whether "Zidovudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 3 | 0 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Zidovudine" by people in Profiles.
-
Increasing the anticancer activity of azidothymidine toward the breast cancer via rational design of magnetic drug carrier based on molecular imprinting technology. Mater Sci Eng C Mater Biol Appl. 2019 Oct; 103:109771.
-
Safety of zidovudine dose reduction in treatment-na?ve HIV infected patients. A randomized controlled study (MiniZID). HIV Med. 2016 Mar; 17(3):206-15.
-
Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug; 11(4):260-8.
-
Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy. Cardiovasc Toxicol. 2007; 7(4):255-63.
-
Association of HIV-1 viral phenotype in the MT-2 assay with perinatal HIV transmission. J Acquir Immune Defic Syndr. 2002 May 01; 30(1):88-94.
-
Ethanol decreases the efficiency of phosphorylation of thymidine kinase in a human T-lymphocytic cell line. Alcohol Clin Exp Res. 2002 Mar; 26(3):295-302.
-
Effect of target cell availability on HIV-1 production in vitro. AIDS. 2002 Feb 15; 16(3):341-5.
-
Inhibition of hematopoietic progenitor cell proliferation by ethanol in human immunodeficiency virus type 1 tat-expressing transgenic mice. Alcohol Clin Exp Res. 2001 Mar; 25(3):450-6.
-
Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001; 10(4):296-307.
-
Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med. 2000 Sep 14; 343(11):759-66.